Targeting the degradation of AXL receptor tyrosine kinase to overcome resistance in gefitinib-resistant non-small cell lung cancer

Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib, remains a major problem in non-small cell lung cancer (NSCLC) treatment. Increased activation of AXL has been identified as a novel mechanism for acquired resistance to EGFR-TKIs in NSC...

Descripción completa

Detalles Bibliográficos
Autores principales: Bae, Song Yi, Hong, Ji-Young, Lee, Hye-Jung, Park, Hyen Joo, Lee, Sang Kook
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4496346/
https://www.ncbi.nlm.nih.gov/pubmed/25760142

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4496346/
https://www.ncbi.nlm.nih.gov/pubmed/25760142

Ejemplares similares